Ischemia, Myocardial Clinical Trial
— DEVISEOfficial title:
Development, Validation and Implementation of a New Quantitative Stress Echocardiographic Test for Myocardial Ischaemia
Patients with chest pain on exertion need a reliable non-invasive test to identify if they
have inducible myocardial ischaemia. This would reduce the use of diagnostic coronary
arteriography, avoid its risks and costs, and guide clinical decisions. Conventional stress
echocardiography has poor reproducibility because it relies on qualitative and subjective
interpretation. Quantitative approaches based on precise and reliable measurements of
myocardial velocity, strain, strain rate and global longitudinal strain have been shown to be
able to accurately diagnose myocardial ischaemia. A more accurate test using myocardial
velocity imaging was not implemented by ultrasound vendors although it provided an objective
measurement of myocardial functional reserve on a continuous scale from normality to severe
ischaemia.
The investigators propose an original approach to create a diagnostic software tool that can
be used in routine clinical practice. The investigators will extract and compare quantitative
data obtained through myocardial velocity imaging and speckle tracking in subjects who
undergo dobutamine stress echocardiography.
The data will be analysed using advanced computational mathematics including multiple kernel
learning and joint statistics applied to multivariate data across multiple dimensions
(including velocity, strain and strain rate traces). This approach will be validated against
quantitative coronary arteriography and fractional flow reserve. The results will be
displayed as parametric images and placed into a reporting tool. The output will determine
the presence and severity of myocardial ischaemia. These new tools will have the capacity for
iterative learning so that the precision of the diagnostic conclusions can be continuously
refined.
Status | Recruiting |
Enrollment | 390 |
Est. completion date | October 31, 2021 |
Est. primary completion date | October 31, 2020 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 20 Years to 89 Years |
Eligibility |
Inclusion Criteria: - Chest pain, chest pain equivalent Exclusion Criteria: - acute coronary syndrome with elevated troponin, severe heart valve disease, uncontrolled hypertension (resting SBP >200mmHg), cardiomyopathy, contraindication to dobutamine, pregnancy |
Country | Name | City | State |
---|---|---|---|
Belgium | UZ Leuven | Leuven | |
Sweden | Danderyd Hospital | Stockholm | |
United Kingdom | University Hospital Wales | Cardiff | |
United Kingdom | Castle Hill Hospital | Cottingham |
Lead Sponsor | Collaborator |
---|---|
University Hospital of Wales | Danderyd Hospital, Hull and East Yorkshire Hospitals NHS Trust, Leuven University, Universitat Pompeu Fabra |
Belgium, Sweden, United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Diagnostic accuracy of quantitative measures of dobutamine stress echocardiography | Echocardiographic measurements of segmental myocardial velocity, strain, strain rate and wall motion scoring referenced against measurements derived from coronary angiography. | 18 months | |
Secondary | Lowest dose of dobutamine to provoke measurable marker of inducible myocardial ischaemia | Using modelling techniques applied predict lowest dose of dobutamine to maintain diagnostic accuracy | 18 months | |
Secondary | Diagnostic accuracy of using machine learning to interpret multiparametric and multidimensional datasets to diagnose myocardial ischaemia | Use modelling to combine pre-test probabilities (based on risk factors such as age), physiological factors (e.g., heart rate) that are associated with longitudinal function and data derived throughout the cardiac cycle (i.e., based on analysis of velocity or strain curves and not just a single value like peak velocity or strain). | 18 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00376532 -
Extracellular Matrix Marker of Arrhythmia Risk (EMMA)
|
N/A | |
Terminated |
NCT00355992 -
The Ischemia Modified Albumin In Diagnosing Ischemic New Events
|
N/A | |
Withdrawn |
NCT03329612 -
Remote Ischemic Preconditioning in ACS Patients
|
N/A | |
Completed |
NCT03586492 -
Coronary Flow Reserve (CFR) in Cardiovascular Risk Stratification
|
N/A | |
Not yet recruiting |
NCT02989077 -
Risk Profiling for Patients With Isolated or Combined Coronary and Cerebral Ischemia, and Current Management Status
|
N/A |